Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
397 hedge funds and large institutions have $6.8B invested in Amedisys in 2020 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 118 increasing their positions, 151 reducing their positions, and 29 closing their positions.
152% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 29
15% more capital invested
Capital invested by funds: $5.9B → $6.8B (+$895M)
12% more funds holding
Funds holding: 354 → 397 (+43)
2.79% less ownership
Funds ownership: 91.82% → 89.03% (-2.8%)
22% less repeat investments, than reductions
Existing positions increased: 118 | Existing positions reduced: 151
34% less call options, than puts
Call options by funds: $41.1M | Put options by funds: $61.9M
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$121M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$51.7M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$45.2M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$17.6M |
| 5 |
JP Morgan Chase
New York
|
+$16.9M |
Top Sellers
AMED Hedge Fund Activity: Q3 2020 in Review
397 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q3 2020, worth a combined $6.8B — up 15% from $5.9B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new AMED positions and 29 closed out — a net gain of 44 holders — while 118 added to existing stakes and 151 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $121M. The largest seller was Carillon Tower Advisers, cutting an estimated $62.8M.
- 397 institutional investors held Amedisys (AMED) as of Q3 2020, up from 354 in Q2 2020.
- Funds reported $6.8B of Amedisys stock for Q3 2020, up 15% quarter-over-quarter.
- 73 funds opened new Amedisys positions in Q3 2020 and 29 closed out, a net change of +44 holders.
- The largest Amedisys buyer in Q3 2020 was Wellington Management Group, an estimated $121M added.
- The largest Amedisys seller in Q3 2020 was Carillon Tower Advisers, an estimated $62.8M sold.
Based on aggregated 13F filings for Q3 2020.